



Horizonte sanitario

ISSN: 1665-3262

ISSN: 2007-7459

Universidad Juárez Autónoma de Tabasco, División
Académica de Ciencias de la Salud

Crisóstomo-Jiménez, Andrea; Morales-Contreras, José Antonio; Juárez-Rojop, Isela Esther; Martínez-López, Mirian Carolina; Ávila-Fernández, Ángela
Analysis of formulations of probiotics accessible to the population of Tabasco, México
Horizonte sanitario, vol. 20, no. 2, 2021, May-August, pp. 179-188
Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud

DOI: <https://doi.org/10.19136/hs.a20n2.4140>

Available in: <https://www.redalyc.org/articulo.oa?id=457868593005>

- How to cite
- Complete issue
- More information about this article
- Journal's webpage in redalyc.org

UAEM  redalyc.org

Scientific Information System Redalyc
Network of Scientific Journals from Latin America and the Caribbean, Spain and
Portugal

Project academic non-profit, developed under the open access initiative

Analysis of formulations of probiotics accessible to the population of Tabasco, México

Análisis de formulaciones de probióticos accesibles a la población de Tabasco, México

Andrea Crisóstomo-Jiménez¹,  José Antonio Morales-Contreras²,  Isela Esther Juárez-Rojop³, 
Mirian Carolina Martínez-López⁴,  Ángela Ávila-Fernández⁵ 

DOI: 10.19136/hs.a20n2.4140

Original Article

Received date: November 22, 2020

Accepted date: January 26, 2021

Corresponding author:

Ángela Ávila-Fernández. Address: Centro de Investigación, DACS-Universidad Juárez Autónoma de Tabasco, Av. Gregorio Méndez no. 2838-A, Col. Tamulte, CP 86150, Villahermosa, Centro, Tabasco, México.
Email: angela.avila@ujat.mx

Abstract

Objective: To analyze the composition of formulations of probiotics sold in establishments in the State of Tabasco or that can be purchased online.

Materials and methods: A descriptive study in which formulations of probiotics sold in 21 establishments in the city of Villahermosa were identified and compared with 30 probiotic supplements sold online. Product information was organized in a database and analyzed according to the dosage form, probiotic genera, species/subspecies contained and their classification as probiotics or synbiotics and as drugs or supplements.

Results: Thirty-one local products and 30 online products formulated with probiotics in 6 different dosage forms were analyzed. Only five local products and no online products are certified by COFEPRIS as drugs. Forty-eight percent of the formulations are monostrain and the rest are multistrain. Seventy-two percent of the formulations are probiotics and the rest are synbiotics. Among the 61 products analyzed, 46 species belonging to 13 different genera were identified, and 39% were common to local and online products. Many of products contain species of the *Lactobacillus* and *Bifidobacterium* genera. The genus *Bacillus* was the only genus that was never combined with other genera in the formulations analyzed in this study.

Conclusions: The population of the state of Tabasco can find at least 31 formulations of probiotics in local establishments. The variety increases if we consider the dietary supplements available for sale online. Multistrain supplements are particularly abundant in online retailers. The products certified by COFEPRIS ensure that the benefits of the formulation are supported by clinical trials in humans and are manufactured following good manufacturing practices.

Keywords: Probiotics; synbiotics; dietary supplements; *Lactobacillus*; *Bifidobacterium*.

Resumen

Objetivo: Analizar la composición de formulaciones de probióticos que se venden en establecimientos del Estado de Tabasco o que se pueden comprar en línea.

Materiales y métodos: Estudio descriptivo en el que se identificaron formulaciones de probióticos comercializados en 21 establecimientos de la ciudad de Villahermosa y se compararon con 30 suplementos probióticos comercializados en línea. La información del producto se organizó en una base de datos y se analizó de acuerdo con la forma de dosificación, los géneros y especies / subespecies de probióticos presentes y su clasificación como probióticos o simbióticos y como medicamentos o suplementos.

Resultados: Se analizaron 31 productos locales y 30 productos de venta en línea formulados con probióticos en 6 formas de dosificación diferentes. Solo cinco productos locales y ningún producto en línea están certificados por COFEPRIS como medicamentos. El 48% de las formulaciones son monocepa y el resto son multicepa. El 72% de las formulaciones son probióticos y el resto son simbióticos. Entre los 61 productos analizados, se identificaron 46 especies pertenecientes a 13 géneros diferentes y el 39% fueron comunes a productos locales y de venta en línea. Muchos de los productos contienen especies de los géneros *Lactobacillus* y *Bifidobacterium*. El género *Bacillus* fue el único que nunca se combinó con otros géneros en las formulaciones analizadas en este estudio.

Conclusiones: La población del estado de Tabasco puede encontrar al menos 31 formulaciones de probióticos en establecimientos locales. La variedad aumenta si tenemos en cuenta los suplementos dietéticos disponibles de venta en línea. Los suplementos multicepa son particularmente abundantes en los productos en línea. Los productos certificados por COFEPRIS aseguran que los beneficios de la formulación están respaldados por ensayos clínicos en humanos y se fabrican siguiendo buenas prácticas de fabricación.

Palabras llave: Probióticos; simbióticos; suplementos dietéticos; *Lactobacillus*; *Bifidobacterium*.

¹ Pasante. Coordinación de Nutrición, División Académica de Ciencias de la Salud. Universidad Juárez Autónoma de Tabasco. México.

² Maestro. Centro de Investigación, División Académica de Ciencias de la Salud. Universidad Juárez Autónoma de Tabasco. México.

³ Doctora. Centro de Investigación, División Académica de Ciencias de la Salud. Universidad Juárez Autónoma de Tabasco. México.

⁴ Doctora. Centro de Investigación, División Académica de Ciencias de la Salud. Universidad Juárez Autónoma de Tabasco. México.

⁵ Doctora. Centro de Investigación, División Académica de Ciencias de la Salud. Universidad Juárez Autónoma de Tabasco. México.

Introduction

According to the Scientific Association of Probiotics and Prebiotics (ISAPP) consensus, probiotics are defined as “live microorganisms which when administered in adequate amounts confer a health benefit”. Microorganisms must be well characterized, be safe, and provide a general benefit to humans, supported by scientific evidence, to be considered probiotics¹. *Lactobacillus*, *Bifidobacterium*, and *Saccharomyces* species are the most commonly used probiotics. Other less frequently used probiotics include species of *Bacillus*, *Propionibacterium*, *Streptococcus*, and *Escherichia*². Evidence supports that probiotics can improve the immune system response, gastrointestinal health, and vaginal lactobacilli concentration. However, they do not promote persistent changes in gut microbiota³.

Formulations containing probiotics must ensure an effective microorganism dose viable until the expiration date to be considered supplements and be allowed to declare a specific beneficial property. In addition, a risk and benefit assessment and the compliance with regulatory standards in each country are required to register the formulations as drugs¹. In addition to probiotics, many formulations include substrates used selectively by host microorganisms that also confer a health benefit (prebiotics). This combination of probiotics and prebiotics is called a synbiotic⁴.

In Mexico, we can find formulations containing probiotics that have been approved by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS, for its acronym in Spanish; <https://www.gob.mx/cofepris>) as drugs. Additionally, we can find formulations described as food or dietary supplements that, in some cases, declare the benefit they confer. The population should know what probiotic products can be purchased on the market and the differences among them when selecting them or recommending their use.

In this study, we identified formulations containing probiotics sold in the State of Tabasco, analyzed their composition, and compared them with formulations that can be purchased online.

Materials and methods

Identification of formulations containing probiotics sold in local establishments.

Nineteen pharmaceutical establishments and two health food stores located in Villahermosa, Tabasco were visited between October and November 2019, and the products formulated with probiotics that are offered to the population were identified. A total of 33 different products were

obtained; two were discarded since no reliable information was found in the scientific literature or in the National Center for Biotechnology Information (NCBI) taxonomy database to support the strain declared on the label. Therefore, this study analyzed the information of 31 products, which we refer to as local products. Some of these products are of national manufacture, while others are imported.

Identification of formulations containing probiotics sold online.

An internet search was carried out using the term probiotic supplement, and information on 30 products that can be purchased online was collected. All these products are imported.

Information recording and data analysis.

The information on local and online products was recorded in a database and analyzed according to several criteria, such as dosage form, genera, species/subspecies of probiotics contained, and classification as probiotics or synbiotics and as drugs or supplements.

Results

It was determined which products formulated with probiotics are sold in 19 pharmacies and two health food stores in Villahermosa by asking the salesmen to identify the probiotic products sold by the establishment. When it was detected that the concept of probiotics was not familiar to the seller, we asked him or her about supplements or medications that help restore or preserve the intestinal flora (the colloquial term used to name the gut microbiota). On some occasions, the best-known probiotic genera (*Lactobacillus*, *Bifidobacterium*, and *Saccharomyces*) were named to guide the seller. In this way, 31 products formulated with probiotics were identified, hereinafter referred to as local products. Likewise, 30 products formulated with probiotics that can be purchased online (products for sale online) were identified and compared with those sold locally.

The establishments visited belong to large pharmaceutical chains that operate regionally (south-southeast of the country) and nationally and have branches in the 17 municipalities of Tabasco. In addition, several of them also offer online sales. Thus, we can assume that the products analyzed as local can be purchased in the 17 municipalities of the State of Tabasco.

Classification of the formulations as drugs or supplements


The 31 local products, along with the 30 products sold online, were classified as supplements or drugs using the label information and verifying their registration by the

Federal Commission for Prevention against Sanitary Risks (COFEPRIS) as drugs. Regarding products sold online, 100% (30) were described on the label as a food supplement and contained warnings that they are not regulated by the FDA. In general, these products stated that they contribute to digestive health. On the other hand, 83.87% (26) of local products were food supplements, and only 16.13% (5) were identified as drugs figure 1, some of which specify on the label their functions as regulators of intestinal flora, assistants in the treatment of diarrhea, or both.

Dosage forms of the formulations analyzed.


Figure 2 shows the dosage forms of the local and online formulations analyzed. The dosage form of 83% (25) of the products sold online was the capsule, and the rest were presented as tablets, chewable tablets, or gummies. By contrast, the variety of dosage forms is better represented in local products: 32% (10) are administered in capsules, 30% (9) in powder, 19% (6) in tablets, and 19% (6) in suspension. The dosage forms common to both types of products were the capsule and the tablet, representing 57% and 13% of the total products, respectively.

Figure 1. Percentage of supplements and drugs formulated with probiotics that are sold locally (31 in total)



Fuente: Elaboración propia

Figure 2. Dosage forms of the formulations analyzed (61 in total).



Fuente: Elaboración propia


Genera and species present in the formulations analyzed.

Species belonging to 8 bacterial genera and five yeast genera were identified in the 61 formulations analyzed. As shown in figure 3, local products contain species from only six genera, while online products contain species from 12 genera. In both cases, the most represented genera were *Lactobacillus* and *Bifidobacterium*. Some local products [64% (20)] and online products [36% (11)] contain species of a single genus, either *Bifidobacterium*, *Lactobacillus*, *Saccharomyces*, or *Bacillus* (Figure 3A and 3B). Unlike local products [22% (7)], 47% (14) of online products contained species of 2 genera, which, in most cases, were a mixture of *Lactobacillus* and *Bifidobacterium* (Figure 3A). In addition, the species *Streptococcus thermophilus* was present in 8 products. It is worth noting that *Bacillus* species were not mixed with species of other genera in any products. Finally, among the online products, there were 2 cases containing species from 10 different genera.

Analyzing the species/subspecies present in the products revealed that 61% (19) of the local products contained a single bacterial species, and 39% (12) contained 2 to 10 different species (Figure 3C). By contrast, 30% (9) of the products sold online contained a single species, while 60% (18) contained 2 to 10 species, and the remaining 10% (3) contained 18 to 31 species from 10 different genera.


Figure 4 shows the 46 species and subspecies identified in the formulations analyzed. Thirty-nine percent (18) were found both in local and in online products, whereas 7% (3) were only present in local products and the remaining 54% (25) were only found in products sold online. *Lactobacillus* was the genus with the highest abundance of species (18) in the formulations analyzed. *Lactobacillus acidophilus*, followed by *L. rhamnosus*, *L. plantarum*, and *L. casei*, were the most represented. In all the products, specific strains of each species were mentioned. Although *Lactobacillus* species diversity in online products was vast, 44% of the species were only present in 3% (2) or less of products.

Figure 3. The Venn-Euler diagram represents the number of formulations containing species from the different genera in local (A) and online products (B), where the set called various genera * represents the genera *Brettanomyces*, *Debaryomyces*, *Kluyveromyces*, *Torulaspora*, and *Leuconostoc*. The number of products that contain a variable number of species/subspecies in their formulation (C).



Fuente: Elaboración propia

Figure 4. Species abundance in the probiotic products analyzed. The total number of species in local products was 21, and the total number of species in online products was 43



Fuente: Elaboración propia

The second most represented genus was *Bifidobacterium*, with seven species. It is worth pointing out that *Bifidobacterium infantis* and *B. lactis* are subspecies of *Bifidobacterium longum* and *B. animalis*, respectively. However, they were described with the old classification due to the importance of subspecies in studying and using probiotics. *B. infantis* is the most abundant subspecies in the infant gut microbiota, and *B. lactis* was discovered in dairy products and has been widely used in their production. The Bifidobacteria species most represented in local products were different from those most represented in the products sold online. In addition, the number of products sold online containing the most represented species [*B. lactis* (53% (16)), *B. bifidum* (40% (12)), and *B. longum* (33% (10))] was elevated compared to the Bifidobacteria species most represented in local products [*B. infantis* (13% (4)) and *B. lactis* (10% (3))]. Few products mentioned specific strains of Bifidobacteria.

The third-most abundant species were yeasts of the genus *Saccharomyces* (5), and only *Saccharomyces boulardii* was common to local and online products. Most of the remaining genera (7) were represented by a single species. *S.*

thermophilus stood out for being the ninth most represented species in all of the products, preceded only by Bifidobacteria and Lactobacillus species.

It should be noted that *Bacillus coagulans* was formerly named *Lactobacillus sporogenes*⁵, and this name is preserved on product labels.

Classification of formulations as probiotics or synbiotics

The 61 formulations analyzed were classified as probiotics or synbiotics using the nutritional information, the list of ingredients declared on the label, or both figure 5. For this, a synbiotic was considered a mixture containing live microorganisms and substrate(s) used selectively by the host microorganisms that confer a health benefit, according to the consensus reported by Swanson in 2020. The substrates mentioned in the labels that allowed classifying the products as synbiotics were inulin, fructooligosaccharides, and oligofructose. It was observed that 32% and 23% of local products and online products, respectively, were synbiotic, even though some were declared as probiotics on the label.

Discussion

The results show that the Tabasco population has access to various supplements and drugs made with probiotics sold by local establishments. Additionally, more complex formulations than those sold locally can be purchased online. It should be noted that only 5 of the 31 local products are registered as drugs by COFEPRIS figure 1. Three of those products contain only *Bacillus clausii* and are administered in suspension (2) and capsule form (1). The other two products are administered in powder form, with one composed of *Saccharomyces boulardii* and the other composed of a mix of *Lactobacillus fermentum* and *L. delbrueckii*. Interestingly, none of the species contained in these drugs was one of the most represented in the 61 formulations analyzed (Figure 4). Multiple studies have demonstrated the effectiveness of *B. clausii* in the treatment of acute diarrhea in children⁶ and *S. boulardii* in reducing the risk of acquiring antibiotic-associated diarrhea in children and adults⁷.

Regulatory approaches in some countries, such as Canada and Italy, agree that products must have a minimum amount of 1×10^9 CFU of well-studied microbial species per serving to be considered probiotic foods or supplements¹. Health Canada lists the following as probiotic species: *Bifidobacterium adolescentis*, *B. animalis* subsp. *animalis*

and *lactis*, *B. bifidum*, *B. breve*, *B. longum* subsp. *longum* and *infantis*, *L. acidophilus*, *L. casei*, *L. fermentum*, *L. gasseri*, *L. johnsonii*, *L. paracasei*, *L. plantarum*, *L. rhamnosus*, and *L. salivarius*. Except for *L. johnsonii*, all these strains were present in at least one formulation that we analyzed (Figure 4). The number of microorganisms declared in the five drugs identified in 64% (17) of local supplements (25) and all products sold online (30) is above 1×10^9 CFU, although some products clarify that this is the amount when manufactured and that the effective number of bacteria until the expiration date is 1×10^7 CFU.

The most commonly used dosage form was the capsule, followed by the tablet figure 2. However, 4 of the five drugs were in powder or suspension form. The strain and the dosage form are critical to ensure that the probiotics remain viable since, after being ingested, the probiotic faces various fluids (bile salts, pancreatic enzymes, gastric juice, among others) during its passage through the gastrointestinal tract⁸. In addition, during encapsulation, factors such as pH, pressure, temperature, moisture content, amount of oxygen, and water activity affect the viability of microorganisms⁹. Improper storage or distribution of these products, or both, can also affect the viability of the microorganisms. Notably, several studies show that probiotics that have been killed, destroyed by heat, or inactivated by ultraviolet light, and even cellular

Figure 5. Classification of the analyzed products (61 in total) as probiotics or synbiotics



Fuente: Elaboración propia

fractions, can confer health benefits and be as effective as living organisms and, in some instances, safer for the host in the treatment of some conditions^{10,11}.

Regarding the complexity of the formulations analyzed, 46% (28) contained only one probiotic strain of the *Lactobacillus*, *Bifidobacterium*, *Saccharomyces*, or *Bacillus* genera, so they were considered monostrains. In contrast, the rest of the formulations were multistrain and contained two to 32 species from 14 different genera figure 3. The abundance of species of the genera *Lactobacillus* and *Bifidobacterium* is evident. These species have been widely studied with favorable results in multiple gastrointestinal tract disorders, such as irritable bowel syndrome, ulcerative colitis, Crohn's disease, and infectious and antibiotic-associated traveler's diarrhea¹². The strain included is essential when choosing probiotic formulations for the treatment of gastrointestinal diseases. *L. acidophilus* LB is effective in the treatment of traveler's diarrhea, while other *L. acidophilus* strains are not¹³. For this reason, the strain must be specified in the formulations.

Although monostrain products are the most studied, the efficacy of multistrain formulations in treating different conditions is being increasingly studied. For example, a probiotic composed of 4 strains of *Lactobacillus* (3) and *Enterococcus* (1) species was well tolerated and associated with a decrease in intestinal inflammation in patients with ulcerative colitis¹⁴. Likewise, a synbiotic formulation composed of fructooligosaccharides and six strains of *Lactobacillus* (4), *Bifidobacterium* (1), and *Bacillus* (1) genera significantly improved glycemic control in subjects with type 2 diabetes mellitus¹⁵. Another formulation with eight strains of *Lactobacillus* (4), *Bifidobacterium* (2), and *Lactococcus* (2) genera given to patients with type 2 diabetes mellitus for six months without prior medication significantly decreased the HOMA-IR index, reduced inflammation, and improved the cardiometabolic profile of patients¹⁶. These findings show that these types of formulations may be a promising adjuvant in antidiabetic therapy. Treating diseases is not the only benefit that can be obtained from ingesting multistrain formulations. The administration of a probiotic composed of 4 strains of *Lactobacillus* (3) and *Saccharomyces* (1) species reduced the toxicity of a mixture of phthalates and bisphenol A in Wistar¹⁷ rats, and very recently, a probiotic formulation of 8 strains of *Lactobacillus* (4), *Bifidobacterium* (3) and *Streptococcus* (1) genera cultivated in consortium from *in vitro* studies showed that it could absorb toxic elements such as Cd, Hg, and Pb. Additionally, the concentration of Cd in the feces of 15-day-old infants whose mothers consumed this formulation was significantly reduced¹⁸. These findings open the possibility of using probiotic consortiums as a method for bioprotection and detoxification of different pollutants. On the other hand,

the addition of different probiotic strains could also be considered a technological strategy. *Lactococcus lactis* and *S. thermophilus* were present in some of the products analyzed, always combined with *Lactobacillus* and *Bifidobacteria*. *L. lactis* and *S. thermophilus* have shown to assist the survival of other lactic acid bacteria in food products¹⁹. In addition, *S. thermophilus* has high oxygen consumption, so it is added to anaerobic microorganisms to reduce the oxygen considered toxic during encapsulation, avoiding affecting the viability of the microorganisms⁹. It has been shown that *L. rhamnosus* GG, the second most represented species in the products analyzed, promotes interactions between crucial elements of the microbiota, such as *Bifidobacteria* and the host epithelium, and significantly modifies the microbiota of healthy individuals²⁰. These properties make it attractive for the formulation of both single and multistrain products.

Among the formulations analyzed, 2 contained 32 species of 10 different genera. The yeasts *Brettanomyces anomalus*, *Debaryomyces hansenii*, *Kluyveromyces marxianus*, and *Torulaspora delbrueckii*, and the four species of *Leuconostoc* were exclusive to these products. These yeasts have been identified and used as starters for various dairy products²¹, whereas various species of *Leuconostoc* have been identified in various fermented products and have shown to inhibit pathogen growth²². In addition to the probiotic strains, these formulations contain some vitamins, minerals, and enzymes that promote digestion. It is important to note that more is not always better. Therefore, it is important to have trials that show that a complex formulation promotes a more significant benefit to consumer health.

Finally, 28% of the products analyzed figure 5 were classified as synbiotic since their components include some prebiotic carbohydrates such as inulin, fructooligosaccharides, and oligofructose. These products are complementary synbiotics since the selective use of prebiotics by autochthonous microbiota has already been established. There are no studies that show that the addition of prebiotics to probiotic formulations leads to a more significant benefit to be considered synergistic synbiotics⁴.

Evidence supporting the benefits conferred by living, dead, or remnants of probiotics, as well as discrepancies in the effectiveness of monostrain and multistrain probiotics in the treatment of several conditions, reinforces the need to have well-characterized formulations supported by *in vitro*, preclinical and clinical trials to ensure that a formulation is effective to promote health or to assist in the treatment of specific conditions¹¹. In addition, scientific evidence should support that more than one strain, additional ingredients, or both in the same formulation provides more significant benefits. In this sense, probiotics registered as drugs by regulatory agencies such as COFEPRIS in Mexico are safer

since this agency certifies that the formulations are supported by clinical trials in humans that prove their benefits and certifies that they have been prepared following good manufacturing practices. The comparison between local and online products shows that although online products widen the variety of formulations that we can purchase, they are marketed in Mexico and abroad following regulations different from those that govern drugs; therefore, they are not required to support the expected benefits with scientific evidence, and consequently, there is no obligation to mention the benefits on the label.

Conclusions

The population of the state of Tabasco can find at least 31 formulations containing probiotics. The variety of products increases if the supplements that can be purchased for sale online are considered, particularly with regard to multistrain supplements. Moreover, online product offerings increase and change quickly. Our findings show that probiotic products that can be purchased in stores and online are not governed by the same health regulations as those found locally. Considering that they are designed with living organisms and that many of their characteristics depend on their viability, health regulations must be reviewed and include aspects that guarantee their quality, especially those declared as supplements. On the other hand, we must not forget that the distribution of any product for sale online does not reach all places, and it is still necessary to have the products available in local establishments. A more in-depth exploration of the local market over time will allow an understanding of if the formulations offered increase and diversify. In addition, exploring the use of probiotics in local clinical practice would be useful to determine if health professionals demand a greater diversity of these products and if they have pertinent information about them to prescribe and recommend them.

Acknowledgments

We thank CONACYT SEP-Ciencia Basica no. 288403 project and 30394 for financial support.

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

1. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*. 2014;11(8):506–14. doi:10.1038/nrgastro.2014.66
2. Sanders ME, Merenstein D, Merrifield CA, Hutkins R. Probiotics for human use. *Nutr Bull*. 2018;43(3):212–25. doi: 10.1111/nbu.12334
3. Khalesi S, Bellissimo N, Vandelanotte C, Williams S, Stanley D, Irwin C. A review of probiotic supplementation in healthy adults: helpful or hype? *Eur J Clin Nutr*. 2019;73(1):24–37. <https://doi.org/10.1038/s41430-018-0135-9>
4. Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. *Nat Rev Gastroenterol Hepatol* [Internet]. 2020;17(11):687–701. <http://dx.doi.org/10.1038/s41575-020-0344-2>
5. Kapse NG, Engineer AS, Gowdaman V, Wagh S, Dhakephalkar PK. Functional annotation of the genome unravels probiotic potential of *Bacillus coagulans* HS243. *Genomics* [Internet]. 2019;111(4):921–9. Available from: <https://doi.org/10.1016/j.ygeno.2018.05.022>
6. Ianiro G, Rizzatti G, Plomer M, Lopetuso L, Scaldaferri F, Franceschi F, et al. *Bacillus clausii* for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2018;10(8). doi:10.3390/nu10081074
7. Szajewska H, Kołodziej M. Systematic review with meta-analysis: *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhea. *Aliment Pharmacol Ther*. 2015;42(7):793–801. doi:10.1111/apt.13344
8. Derrien M, van Hylckama Vlieg JET. Fate, activity, and impact of ingested bacteria within the human gut microbiota. *Trends Microbiol* [Internet]. 2015;23(6):354–66. <http://dx.doi.org/10.1016/j.tim.2015.03.002>
9. Šipailienė A, Petraitytė S. Encapsulation of Probiotics: Proper Selection of the Probiotic Strain and the Influence of Encapsulation Technology and Materials on the Viability of Encapsulated Microorganisms. *Probiotics Antimicrob Proteins*. 2018;10(1):1–10. <https://doi.org/10.1007/s12602-017-9347-x>

10. Kataria J, Li N, Wynn JL, Neu J. Probiotic microbes: Do they need to be alive to be beneficial? *Nutr Rev.* 2009;67(9):546–50. doi:10.1111/j.1753-4887.2009.00226.x
11. Zendeboodi F, Khorshidian N, Mortazavian AM, da Cruz AG. Probiotic: conceptualization from a new approach. *Curr Opin Food Sci* [Internet]. 2020;32:103–23. Available from: <https://doi.org/10.1016/j.cofs.2020.03.009>
12. Islam SU. Clinical Uses of Probiotics. *Medicine (Baltimore)*. 2016;95(5). DOI: 10.1097/MD.0000000000002658
13. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. *PLoS One*. 2012;7(4). doi:10.1371/journal.pone.0034938
14. Bjarnason I, Sission G, Hayee BH. A randomised, double-blind, placebo-controlled trial of a multistrain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. *Inflammopharmacology* [Internet]. 2019;27(3):465–73. <https://doi.org/10.1007/s10787-019-00595-4>
15. Madempudi RS, Ahire JJ, Neelamraju J, Tripathi A, Nanal S. Efficacy of UB0316, a multistrain probiotic formulation in patients with type 2 diabetes mellitus: A double blind, randomized, placebo controlled study. *PLoS One*. 2019;14(11):1–16. <https://doi.org/10.1371/journal.pone.0225168>
16. Sabico S, Al-Mashharawi A, Al-Daghri NM, Wani K, Amer OE, Hussain DS, et al. Effects of a 6-month multistrain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial. *Clin Nutr* [Internet]. 2019;38(4):1561–9. <https://doi.org/10.1016/j.clnu.2018.08.009>
17. Baralić K, Živančević K, Javorac D, Buha Djordjevic A, Anđelković M, Jorgovanović D, et al. Multistrain probiotic ameliorated toxic effects of phthalates and bisphenol A mixture in Wistar rats. *Food Chem Toxicol*. 2020;143(May). <https://doi.org/10.1016/j.fct.2020.111540>
18. Astolfi ML, Protano C, Schiavi E, Marconi E, Capobianco D, Massimi L, et al. A prophylactic multistrain probiotic treatment to reduce the absorption of toxic elements: In-vitro study and biomonitoring of breast milk and infant stools. *Environ Int* [Internet]. 2019;130(January):104818. Available from: <https://doi.org/10.1016/j.envint.2019.05.012>
19. Dixit Y, Wagle A, Vakil B. Patents in the Field of Probiotics, Prebiotics, Synbiotics: A Review. *J Food Microbiol Saf Hyg*. 2016;01(02):1–13. doi: 10.4172/2476-2059.1000111
20. Eloie-Fadrosch EA, Brady A, Crabtree J, Drabek EF, Ma B, Mahurkar A, et al. Functional dynamics of the gut microbiome in elderly people during probiotic consumption. *MBio*. 2015;6(2):1–12. doi:10.1128/mBio.00231-15
21. Andrade RP, Oliveira DR, Lopes ACA, de Abreu LR, Duarte WF. Survival of *Kluyveromyces lactis* and *Torulaspora delbrueckii* to simulated gastrointestinal conditions and their use as single and mixed inoculum for cheese production. *Food Res Int* [Internet]. 2019;125(March):108620. <https://doi.org/10.1016/j.foodres.2019.108620>
22. Shao X, Fang K, Medina D, Wan J, Lee J-L, Hong SH. The probiotic, *Leuconostoc mesenteroides*, inhibits *Listeria monocytogenes* biofilm formation. *J Food Saf*. 2020;40(2). DOI: 10.1111/jfs.12750

Appendix 1. Local and online products included in this study.

Local products		Online products	
Name (Manufacturer or distributor)	Dosage form	Name (Manufacturer or distributor)	Dosage form
Enterogermina (Sanofi)*	Suspension	Align Probiotic (Align)	Capsule
Sinuberase (Laboratoire Unither)*	Suspension	Align Digestive Care Probiotic (Align)	Capsule
Sinuberase (Laboratoire Unither)*	Capsule	Align Fuerza Extra (Align)	Capsule
Lacteol fort (Carnot)*	Powder	Kids daily probiotic (Culturelle)	Chewable tablet
Floratil (Biocodex 1)*	Powder	Digestive Health Extra Strength (Culturelle)	Chewable tablet
Esporas de Bacillus clausii (Laboratoire Unither)	Suspension	Probiotix complex (GNC)	Capsule
Lactipan baby (Italmex pharma)	Suspension	Ultra 50 Probiotic Complex (GNC)	Capsule
Lactipan Kids (Italmex pharma)	Suspension	Probiotix (GNC)	Capsule
Lactipan (Italmex pharma)	Powder	Probiotic solutions with enzymes (GNC)	Capsule
Simi bacilos forte (Manufacturas Naturex)	Capsule	RAW probiotics women (Garden of life)	Capsule
Simi probacilus (Manufacturas Naturex)	Tablet	RAW probiotics colon care (Garden of life)	Capsule
Simi Próbóticos (Laboratorios Vimex)	Powder	Ultimate cultures complex (Mayfair nutrition)	Capsule
Simi Próbóticos (Manufacturas Naturex)	Tablet	Mycrobiome probiotic (Mayfair nutrition)	Capsule
Protectis (TwoPac AB)	Suspension	Alkabiotics 7 probioticos (Alka balance)	Capsule
Lactobacillus (Manufacturas Naturex)	Capsule	PRO-Moms (Hyperbiotics)	Tablet
Bioflavonoides, Lactobacillus y vitamina C (Manufacturas Naturex)	Tablet	PB8 probiotic (PB8)	Capsule
Zulik (Manufacturas Naturex)	Tablet	4-strain probiotic (Walgreens)	Capsule
Lactiv sp (Manufacturas Naturex)	Tablet	Probiotic (Walgreens)	Capsule
Lactiv kids (Manufacturas Naturex)	Tablet	Probiotic with <i>Sacharomyces boulardii</i> (Walgreens)	Capsule
Lactiv kids (Manufacturas Naturex)	Powder	Super Probiotic (Walgreens)	Capsule
Lactiv inulina y probióticos (Manufacturas Naturex)	Powder	Daily probiotic (Walgreens)	Capsule
Lactobacilos (Gelpharma)	Capsule	Probiotic gummies (Walgreens)	Gummy
Proviover (Manufacturas Naturex)	Capsule	Nighttime probiotic (Walgreens)	Capsule
Probiolog IBS (Laboratoires Mayoly splinder)	Powder	Daytime probiotic (Walgreens)	Capsule
Glutapak R (Victus)	Powder	Ultimate probiotic (Walgreens)	Capsule
Probiomax (Natutech)	Capsule	Fiber and probiotic (Walgreens)	Capsule
Vivera (Probiotal)	Powder	Mature adult probiotic (Walgreens)	Capsule
Probiotic complex (GNC)	Capsule	Children's probiotic chewable tablets whit lactobacillus rhamnosus GG (Walgreens)	Tablet
Probiotix (Bioleven)	Capsule	Women's probiotic (Walgreens)	Capsule
D- Galac (Biomiral)	Capsule	Probiotic colon support (Walgreens)	Capsule
Proteflor (Siegfried Rhein)	Capsule		

* Products registered by COFEPRIS.